Management of Cholestatic Liver Injury

Diagnostic Evaluation

A comprehensive diagnostic evaluation for other causes of intrahepatic cholestasis, including primary sclerosing cholangitis, drug-induced liver injury, infiltrative diseases, and metabolic conditions, is recommended for patients with a mixed cholestatic-hepatocellular pattern, as seen in patients with elevated ALP and GGT, and concurrent hepatocellular component, as indicated by elevated ALT 1
The American Association for the Study of Liver Diseases recommends calculating FIB-4 or NAFLD Fibrosis Score for fibrosis risk stratification in patients with suspected NAFLD 2, 3
The European Association for the Study of the Liver suggests assessing metabolic syndrome components, including waist circumference, blood pressure, fasting lipids, and fasting glucose or HbA1c, in patients with NAFLD 2, 3

MRCP is essential to evaluate for primary sclerosing cholangitis, which can present with normal ultrasound but abnormal bile ducts on MRCP, particularly in patients with inflammatory bowel disease history 1
The American College of Gastroenterology recommends serum protein electrophoresis if infiltrative disease is suspected, and serum IgG4 levels to exclude IgG4-related cholangiopathy 1
Iron studies, including serum iron, TIBC, and ferritin, should be performed to exclude hemochromatosis, and ceruloplasmin and 24-hour urine copper should be measured if age <40 to exclude Wilson disease 1

The American Association for the Study of Liver Diseases recommends weight loss of 7-10% body weight through caloric restriction and exercise for patients with NAFLD, as well as restricting saturated fat to <7% of total calories 2, 3, 4
Statins are not contraindicated and may be beneficial for cardiovascular risk in patients with NAFLD 4
Referral to hepatology is recommended if ALT >8× ULN or >5× baseline, ALT >3× ULN with total bilirubin >2× ULN, or evidence of synthetic dysfunction, such as elevated INR or low albumin 1, 4

Repeat liver enzymes in 2-3 months to establish trend, and if all testing is unremarkable and enzymes remain <3× ULN, lifestyle modification trial is appropriate 1
84% of abnormal liver tests remain abnormal at 1 month, and 75% at 2 years, so spontaneous resolution should not be assumed 4